Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viracept for CMV Retinitis in AIDS Patients
NCT00002169Phase 2Completed
- Sponsor
- Agouron Pharmaceuticals
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Viracept with Placebo (2 arms). Primary endpoint: Clinical Outcome of Cytomegalovirus (CMV) Retinitis. Status: completed.
02
Drugs
nelfinavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002169.